Blood Podcast

Today we’ll review data on the high frequency of germline RUNX1 mutations in patients with acute myeloid leukemia, learn more about the development of an international prognostic score that predicts time to first treatment in CLL patients with early, asymptomatic disease, and explore the possibility of improving the activity of virus-directed immunotherapies against certain types of EBV tumors.

In this week’s episode we’ll learn why anticoagulation may play a role in the prevention of vaso-occlusive events in sickle cell disease, review data that could help predict the risk of VTE and bleeding in hospitalized patients, and find out if Ruxolitinib is a viable treatment of steroid-refractory acute graft-versus-host disease.

This week’s episode will review a report on a new mouse model with an enhanced ability to support human hematopoietic and tumor engraftment, explore more about increased mTOR activation in idiopathic multicentric Castleman disease, and assess the feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL.

This week’s episode will review the incidence and fate of clonal hematopoiesis among donors and recipients of related allogeneic hematopoietic stem cell transplantation, examine the manifestations and clinical course of patients with a particular subtype of Fanconi anemia, and assess three clinical studies that demonstrate high rates of efficacy and low rates of toxicity of daratumumab in patients with previously treated AL amyloidosis.

This week’s episode will highlight the development of a factor VIII replacement therapy for patients with severe Hemophilia A, examine a novel pathway of resistance of FLT3-ITD+ AML cells to FLIT3 inhibitors, and review long-term results of a pilot study in children with low risk B-cell ALL conducted in a limited-resource setting.

In this bonus podcast episode, Drs. Nancy Berliner and Laurie Sehn lead a discussion on this series of authoritative reviews on a collection of rare systemic hematologic disorders that are frequently difficult to recognize, diagnose, and treat. The series highlights new genomic and proteomic insights that inform our understanding of their pathophysiology and treatment.Review Series on Rare Systemic Hematologic Disorders

This week’s episode will review evidence that selecting donors with specific types of natural killer cells leads to improved outcome in stem cell transplantation, review an analysis of platelet transfusion in cerebral hemorrhage, and explore the challenges of diagnosing recurrent ipsilateral deep vein thrombosis.

This week’s episode will examine data on the impact of the FDG uptake level on predicting subsequent high-grade histological transformation in follicular lymphoma, explore clonal tracking in gene therapy patients as a method for understanding human hematopoiesis, and review a study on the recognition of platelet factor 4-von Willebrand factor complexes by heparin-induced thrombocytopenia antibodies as a basis for the pathogenesis of HIT.

In this week’s episode we’ll learn about novel insights into the link between innate immune responses and activation of coagulation during gram-negative sepsis, examine the impact of GPRASP proteins on hematopoietic stem cell transplantation, and explore the dynamics of clonal hematopoiesis in anemia of older individuals.

This week’s episode will review data on spliceosomal gene mutations, evaluate the impact of Ruxolitinib on weight gain, and assess the effect of compliment blockade with eculizumab on high risk patients with stem cell transplant associated thrombotic microangiopathy.

This week’s episode will review the clinical correlates of NT5C2 mutations in relapsed ALL, the impact of Crovalimab, a recycling monoclonal antibody against complement component C5 in paroxysmal nocturnal hemoglobinuria, and the relationship between leukocyte NADPH oxidase and leukotriene B4 and neutrophilic inflammation in the context of chronic granulomatous disease

This week’s episode will review a novel treatment for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis, learn more about the behavior of leukemic clones in patients with acute myeloid leukemia receiving venetoclax-based combination therapies, and review the role of the integrin alpha9beta1 in arterial thrombosis.

This week's episode will explore interventions that may improve outcomes in sepsis by stabilizing neutrophil extracellular traps, or NETs, discuss the use of a novel strategy to generate CAR T cells that react with surface antigens on AML cells, and review data about how chronic lymphocytic leukemia cells become resistant to Venetoclax.

In this episode Dr. Catherine Bollard, Blood Associate Editor provides highlights of this commissioned review series Understanding and Treating Primary Immunodeficiency, that highlights cutting-edge developments in the biology and management of primary immune deficiencies.Review Series on Understanding and Treating Primary Immunodeficiency

This week's episode will review efforts to improve the activity of CAR T cells, explore the impact of Protein C activator AB002 on thrombus development, and look at results from a UK study on minimal residual disease status and outcome after transplantation in NPM1-mutated AML.

This week’s episode will examine how graft versus host disease in the colon is driven by an inflammatory cytokine produced by specialized donor T cells, review a prospective, multicenter study to assess the frequency and clinical relevance of low level mutations in chronic myeloid leukemia, and learn about a potential new therapeutic that blocks the activity of the iron-regulatory hormone Erythroferrone to reduce iron overload in thalassemia.

This week’s episode will review treatment for secondary prevention of venous thromboembolism in children, a therapeutic strategy for relapsed or refractory B-cell acute lymphoblastic leukemia, Ivosidenib monotherapy in patients with newly diagnosed AML with mutations in the isocitrate dehydrogenase 1 gene, and survival outcomes of chronic Lymphocytic Leukemia patients treated with Ibrutinib.

This week’s episode will examine the critical role of platelet necrosis in ischemic stroke injury, the discovery of the molecular basis for the PEL blood group, and the impact of NPM1/FLT3-ITD genotypes in patients with acute myeloid leukemia.

In this episode we welcome Drs. Thomas Ortel, Jeffrey Weitz, and Kenneth Bauer as they discuss the Blood Review Series on the Treatment of Venous Thrombotic Disorders. In this review series, experts contribute 6 seminal reviews that focus on the treatment of venous thromboembolism (VTE) in adults and children, the management of VTE developing in unusual locations and in the setting of thrombophilia, and new targets and antithrombotic therapies in development.Review Series on Treatment of Venous Thrombotic Disorders

In this episode we’ll examine a new strategy to improve the durability of remission after CAR T-cell therapy for pediatric B cell leukemia, explore the genomic landscape of Breast Implant-Associated Anaplastic Large Cell Lymphomas, and discuss a new report showing that the occurrence of arterial thrombotic events following the diagnosis of myeloproliferative neoplasms is associated with a significantly increased risk of a second cancer.

Today we’ll examine the role of heredity vs. environmental factors in the evolution of age-related clonal hematopoiesis, review the first systematic approach to uncover all possible activating point mutations within and around the transmembrane domain of the thrombopoietin receptor in myeloproliferative neoplasms, and discuss the role of complement activation and mutations in complement regulatory genes in patients with thrombotic or catastrophic antiphospholipid syndromes.

In this episode we highlight the development of intensified T-cell acute lymphoblastic leukemia-focused protocols, the use of a thrombopoietin agonist for thrombocytopenia following allogeneic hematopoieticstem cell transplantation, and a crucial step forward in the development of miRNA therapies targeting myeloid diseases.

This episode will explore the consequences of a loss of the interaction between mutant calreticulin and another ER resident protein, and how this may promote myeloproliferative neoplasms, the role of a calcium-induced transcription factor in driving diffuse large B-cell lymphoma signaling, and a comparison of two therapies for standard risk acute graft-versus-host disease.

This episode will highlight a unique treatment for refractory hematologic malignancies, therapy-induced mutations impacting the genomic landscape of relapsed acute lymphoblastic leukemia, and a unique approach to avoiding chronic graft-versus-host disease.

The topics in this episode include studies on the mechanism of progression in myelodysplastic syndromes, the value of gait speed as a predictor of outcomes in older adults with hematologic malignancies, the role of extended eltrombobag therapy on severe aplastic anemia, and the role of the Hedghog pathway mutations in chronic lymphocytic leukemia.

This episode highlights articles and commentaries that help expand our understanding of prognostic biomarkers in CLL, learn more about a streamlined analysis of the granulocyte transcriptome in myeloproliferative neoplasms, explore the role of neutrophil extra cellulartraps in adenosine deaminase deficiency, and examine the function of the plant homeodomain-like finger protein 6, in hematopoietic stem cell self-renewal.

This episode explores four compelling topics which include: Hemophagocytic Lymphohistiocytosis, a severe and potentially fatal systemic inflammatory syndrome, CAR T-cell therapy in follicular lymphomas, Sickle Cell Anemia and sickle trait in thrombosis, and mutated calreticulin in myeloproliferative disorders.

This episode discusses the immune engine in classical Hodgkin Lymphoma, osteopontin’s keyrole in the chemoattraction of neutrophils in transfusion-related acute lunginjury,B-1 progenitor acute lymphoid leukemia, and exciting new ideas for heparin-induced thrombocytopenia treatment.

The article highlighted in this trailer "The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells" was published June 6, 2019; Blood, Volume 133, Issue 23. The authors of this article are: Satoru Miyagi , Patrycja Sroczynska , Yuko Kato , Yaeko Nakajima-Takagi , Motohiko Oshima , Ola Rizq , Naoya Takayama , Atsunori Saraya , Seiya Mizuno , Fumihiro Sugiyama , Satoru Takahashi , Yumi Matsuzaki , Jesper Christensen , Kristian Helin , Atsushi Iwama.